Tigit- and light-based chimeric proteins
AssigneeShattuck Labs, Inc.
InventorsTaylor SCHREIBER, George FROMM, Suresh DE SILVA
Life of this patent
Estimating the term…
Abstract
The present invention relates, inter alia, to compositions and methods, including TIGIT- and/or LIGHT-based chimeric proteins that find use in the treatment of disease, such as cancer and an inflammatory disease.
Claims47
A chimeric protein of a general structure of:
- N terminus-(a)-(b)-(c)-C terminus,
- wherein:
- (a) is a first domain comprising an extracellular domain of a Type I transmembrane protein, the transmembrane protein being TIGIT,
- (b) is a linker comprising at least one cysteine residue capable of forming a disulfide bond, and
- (c) is a second domain comprising an extracellular domain of Type II transmembrane protein, the transmembrane protein being selected from 4-1BBL, GITRL, TL1A, and LIGHT, wherein:
- the linker connects the first domain and the second domain and optionally comprises one or more joining linkers, such joining linkers being selected from SEQ ID NOs:
- 49-95.
A chimeric protein of a general structure of:
- N terminus-(a)-(b)-(c)-C terminus,
- wherein:
- (a) is a first domain comprising an extracellular domain of a Type I transmembrane protein, the transmembrane protein being selected from PD-1, CD172a(SIRPα), and TIGIT,
- (b) is a linker comprising at least one cysteine residue capable of forming a disulfide bond, and
- (c) is a second domain comprising an extracellular domain of Type II transmembrane protein, the transmembrane protein being LIGHT, wherein:
- the linker connects the first domain and the second domain and optionally comprises one or more joining linkers, such joining linkers being selected from SEQ ID NOs 49-95.
A method for treating cancer or an inflammatory disease comprising administering an effective amount of a pharmaceutical composition to a subject in need thereof, the pharmaceutical composition comprising a chimeric protein comprising:
- (a) a first domain comprising an extracellular domain of a Type I transmembrane protein, the transmembrane protein being TIGIT,
- (b) a linker comprising at least one cysteine residue capable of forming a disulfide bond, and
- (c) a second domain comprising an extracellular domain of a Type II transmembrane protein, the transmembrane protein selected from 4-1BBL, GITRL, TL1A, and LIGHT.
A method for treating cancer or an inflammatory disease comprising administering an effective amount of a pharmaceutical composition to a subject in need thereof, the pharmaceutical composition comprising a chimeric protein comprising:
- (a) a first domain comprising an extracellular domain of a Type I transmembrane protein, the transmembrane protein selected from PD-1, CD172a(SIRPα), and TIGIT,
- (b) a linker comprising at least one cysteine residue capable of forming a disulfide bond, and
- (c) a second domain comprising an extracellular domain of Type II transmembrane protein, the transmembrane protein being LIGHT.
Dependencies are inferred from the claim text.